Evidence for Reduction in Breakpoints Used To Determine Vancomycin Susceptibility in Staphylococcus aureus
Open Access
- 1 September 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (9) , 3982-3983
- https://doi.org/10.1128/aac.49.9.3982-3983.2005
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus BacteremiaJournal of Clinical Microbiology, 2004
- Endocarditis Caused byStaphylococcus aureuswith Reduced Susceptibility to VancomycinClinical Infectious Diseases, 2004
- Clinical Features Associated with Bacteremia Due to Heterogeneous Vancomycin‐IntermediateStaphylococcus aureusClinical Infectious Diseases, 2004
- Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterizationDiagnostic Microbiology and Infectious Disease, 2003
- Epidemiological and Microbiological Characterization of Infections Caused byStaphylococcus aureuswith Reduced Susceptibility to Vancomycin, United States, 1997–2001Clinical Infectious Diseases, 2003
- Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to GlycopeptidesJournal of Clinical Microbiology, 2001
- A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospitalJournal of Antimicrobial Chemotherapy, 2001
- Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infectionsInternational Journal of Antimicrobial Agents, 2000
- Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycinThe Lancet, 1999
- Infective EndocarditisClinical Infectious Diseases, 1993